September 9, 2021

Don’t Miss These Cannabis Stocks

Midas Letter
Midas Letter
Don't Miss These Cannabis Stocks

Are you an investor who is looking for what could be the next weed stock to take over the next US state? Or an investor looking for an undervalued cannabis stock to its peers? Or maybe an investor who loves company fundamentals and wants to know the best performing marijuana stock in the latest round of financials? In any case, Charles Taerk, CEO Faircourt Asset Management Inc CEO and Ninepoint Alternative Health Fund portfolio manager, has you covered detailing the cannabis stocks you don’t want to miss.

As the cannabis industry grows and more markets come online through state-level legalization, new companies always provide opportunities for investors. U.S. MSOs have extremely attractive valuations – especially when compared to other growth sectors like tech, trading at significantly higher valuations. In this vein, there are a few noteworthy marijuana companies whose stocks shouldn’t be overlooked from their latest financials and steps towards growth.

The Ninepoint Alternative Health Fund is always up to date with the latest happenings within the cannabis market globally. The fund has a 1-year positive return of 37.42% as of July 30 – a hard task in today’s weed stock climate. The fund has some fundamental theses, including capitalizing on the rise in healthcare expenditures, driven by an ageing global population, pushing consumers to seek cheaper alternatives to treat chronic conditions. In addition, with the legalization of cannabis, the industry is anticipating high growth in medical and recreational use, and accordingly, the funds top 3 funds are:

  1. Columbia Care Inc (CNSX:CCHW, OTCMKTS:CCHWF)
  2. Cresco Labs Inc (CNSX:CL, OTCMKTS:CRLBF)
  3. Curaleaf Holdings Inc (CNSX:CURA, OTCMKTS:CURLF)


Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.